TITLE

Adrenocortical Carcinoma Treated with o,p'-DDD

AUTHOR(S)
Montgomery, D. A. D.; Welbourn, R. B.
PUB. DATE
May 1965
SOURCE
British Medical Journal;5/22/1965, Vol. 1 Issue 5446, p1356
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64058818

 

Related Articles

  • o,p'DDD therapy in invasive adrenocortical carcinoma. Becker, Dennis; Schumacher, O. Peter; Becker, D; Schumacher, O P // Annals of Internal Medicine;May75, Vol. 82 Issue 5, p677 

    Invasive adrenocortical carcinoma was diagnosed in two patients, 3 1/2 and 69 years of age, respectively. Therapy with o,p'DDD was begun immediately, and the patients have survived 4 1/12 and 7 9/12 years, respectively. The prolonged survival represents possible "cure" of inoperable disease...

  • Endocrine and metabolic diseases. Besser, G.M.; Jeffcoate, W.J. // British Medical Journal;2/21/1976, Vol. 1 Issue 6007, p448 

    Examines the diseases in the endocrine glands and the disorders in the metabolism of human. Causes of Cushing's syndrome; Treatment of adrenocortical adenoma; Effectiveness of mitotane in treating adrenal carcinoma.

  • Myxoid adrenal cortical carcinoma--a rare variant of adrenocortical carcinoma. Suresh, B.; Kishore, T. A.; Albert, A. S.; Joy, A. // Indian Journal of Medical Sciences;Nov2005, Vol. 59 Issue 11, p505 

    Presents a letter to the editor about adrenocortical carcinomas.

  • Open adrenalectomy viable option in adrenocortical cancer. Altersitz, Katrina; Costa, Samantha // Endocrine Today;Feb2014, Vol. 12 Issue 2, p25 

    The article reports on the findngs of a study which indicate that patients with adrenocortical carcinoma must be treated with open adrenalectomy and must consider mitotane therapy in conjuntion with radiation to delay tumor recurrence.

  • Adrenocortical Carcinoma Presenting with Signs of Acute Abdomen. Symeonidis, Dimitrios; Chatzinikolaou, Ioannis; Koukoulis, Georgios; Mamaloudis, Ioannis; Tepetes, Konstantinos // Case Reports in Surgery;2013, p1 

    Background. Adrenocortical carcinomas represent rare malignancies. In cases of hormone-secreting tumors, the hormone in excess determines the nearly diagnostic clinical presentation. Biologically inert tumors are diagnosed either due to the mass effect or incidentally. The purpose of the present...

  • Adrenocortical carcinoma: a diagnostic and treatment dilemma. Khan, Sheraz; Imtiaz, Komal E. // British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p46 

    The article offers information on the treatment and diagnosis of adrenocortical carcinoma in Great Britain. Eventhough laparoscopic adrenalectomy is a proven standard for treating adrenal tumors, it is not indicated for a tumour of any size when invasion of surrounding tissues are clearly...

  • Adrenocortical carcinoma drug starts phase 1 trial, gains orphan drug status.  // Endocrine Today;Nov2013, Vol. 11 Issue 11, p9 

    The article reports on the phase one clinical trial of ATR-101, a drug designed to treat adrenocortical carcinoma, initiated by drug company Atterocor Inc., and the orphan drug designation granted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency to the drug.

  • Endocrine Society issues guidelines for aldosteronism.  // Endocrine Today;10/10/2008, Vol. 6 Issue 18, p15 

    The article focuses on the guidelines issued by the Endocrine Society for aldosteronism. It recommended using adrenal computed tomography scans to exclude adrenocortical carcinoma in patients. For patients diagnosed with primary aldosteronism before age 20, genetic testing for...

  • Contemporary management of adrenocortical carcinoma. Guthrie Jr., Troy; Jasani, Nikesh // Cancer Therapy;2008, Vol. 6 Issue 2, p597 

    Adrenocortical carcinoma is a rare malignancy with a high mortality rate. Management of adrenocortical carcinoma has evolved with most advances occuring in the past decade. This review will touch on the pathogenesis, epidemiology and diagnosis of adrenocortical carcinoma. The article will focus...

  • Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Imataki, Osamu; Makimoto, Atsushi; Kojima, Rie; Sakiyama, Michiyo; Hosono, Ako; Takaue, Yoichi // International Journal of Clinical Oncology;Apr2006, Vol. 11 Issue 2, p156 

    Adrenocortical carcinoma is a rare malignancy in adolescents and young adults. The prognosis of unresectable/metastatic adrenocortical carcinoma remains very poor because the rarity of the tumor has made it difficult to establish treatment guidelines, and diagnosis and the resultant treatment...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics